Sandoz voluntarily recalls 24 lots of injectable methotrexate

10/27/2010 | Reuters

Novartis' Sandoz unit is recalling 24 lots of methotrexate, an injectable chemotherapy drug, after discovering glass particulates in the product. The recall affects vials of 50 milligrams per 2 milliliters and 250 milligrams per 10 milliliters. Sandoz has not received reports of adverse effects concerning the drug.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Compliance Analyst
ACell, Inc.
Columbia, MD
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
European Sales Manager
SentreHEART, Inc.
Germany, Benelux, UK